ReviewClinical medicine (London, England)2019
Chikungunya arthritis.
Review in Clinical medicine (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 92 citations in OpenAlex.
- Article
- A machine learning approach for differential classification of chikungunya virus: an explainable AI study based on surveillance data.Infection · 2026Article
- Tupaia belangeri better reflects the typical symptoms of Chikungunya virus infection than mice: A comparative study.Virologica Sinica · 2026Article
- Emetine dihydrochloride inhibits Chikungunya virus nsP2 helicase and shows robust antiviral activity in cells and mice.Journal of biomedical science · 2026Article
- Early Immune Hypoactivation and Persistent Innate Reprogramming Characterize Chronic Chikungunya Disease.bioRxiv : the preprint server for biology · 2026Article
- Chikungunya in 2025: Comprehensive Insights into Virology, Diagnostics, Vaccines, and Antiviral Therapies.Viruses · 2026Review
- Unraveling chikungunya's viral tapestry through molecular mechanisms and clinical insights.Infectious diseases & immunity · 2026Review
- Chikungunya Virus in 2025: Epidemiology, Immunopathogenesis, and Vaccine Development - A Narrative Review.Infection and drug resistance · 2026Review
- The Re-emergence of Chikungunya in Sri Lanka: A Genomic investigation.medRxiv : the preprint server for health sciences · 2025Article
- Clinical and laboratory profiles of dengue infection in the hospitals in North Jakarta, Indonesia.IJID regions · 2025Article
- Current and future advances in practice: arboviral arthritides.Rheumatology advances in practice · 2025Review
- [Acute polyarthritis after a stay in the Caribbean].Innere Medizin (Heidelberg, Germany) · 2024Article
- Temperature Interference on ZIKV and CHIKV Cycles in Mosquitoes and Mammalian Cells.Pathogens (Basel, Switzerland) · 2024Article
- Development of Proniosome Gel Formulation for CHIKV Infection.Pharmaceutics · 2024Article
- Longitudinal analysis of post-acute chikungunya-associated arthralgia in children and adults: A prospective cohort study in Managua, Nicaragua (2014-2018).PLoS neglected tropical diseases · 2024Article
- Salicylic Acid Conjugate of Telmisartan Inhibits Chikungunya Virus Infection and Inflammation.ACS omega · 2024Article
- Chikungunya Virus, Metabolism, and Circadian Rhythmicity Interplay in Phagocytic Cells.Metabolites · 2023Review
- Chikungunya fever.Nature reviews. Disease primers · 2023Review
- Cognitive impairment in post-acute sequelae of COVID-19 and short duration myalgic encephalomyelitis patients is mediated by orthostatic hemodynamic changes.Frontiers in neuroscience · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The chikungunya virus (CHIKV) infection epidemic has emerged as a significant public health concern in the last 10-15 years, especially in Asian and south American countries. However, with ever-expanding tourism and migration, cases have now been reported in north America and Europe. CHIKV infection predominantly causes musculoskeletal symptoms with a chronic polyarthritis which may resemble autoimmune inflammatory arthritis. CHIKV infection should always be suspected in a returning traveller presenting with fever, skin rash and arthralgia. Though first reported in the last century, a series of epidemics since 2004 have substantially improved our knowledge. There has also been a significant increase in our understanding of the immunopathogenesis of chikungunya infection. This knowledge is being used in the development of new treatment strategies and preventive measures. In this narrative review, we discuss some of the recent advances in the epidemiology, immunopathogenesis, and management of CHIKV arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.